小剂量重组组织型纤溶酶原激活物与尿激酶治疗急性心肌梗死的对比研究

目的：评价小剂量重组组织型纤溶酶原激活物（ｒｔＰＡ）静脉溶栓治疗国人急性心肌梗死（ＡＭＩ）的疗效及安全性。方法：６６例ＡＭＩ患者随机分为ｒｔＰＡ组３１例及尿激酶（ＵＫ）组３５例，分别应用ｒｔＰＡ及ＵＫ治疗。结果：心肌梗死相关血管再通率ｒｔＰＡ组８０．６％与ＵＫ组４８．６％比较，Ｐ＜０．０５；４周住院病死率ｒｔＰＡ组０与ＵＫ组８．６％比较，Ｐ＜０．０５；而２组间出血发生率无差异。结论：小剂量ｒｔＰＡ治疗ＡＭＩ血管再通率高，出血并发症少，可降低ＡＭＩ早期病死率，是一种安全有效的溶栓剂

The comparison of intravenous thrombolytic therapy with low dose recombinant tissue type plasminogen activator and urokinase in patients with acute myocardial infarction

Objective:To evaluate the clinical efficacy and safety of intravenous thrombolytic therapy using low dose recombinant tissue plasminogen activator (rtPA) in Chinese patients with acute myocardial infarction (AMI).Methods:66 cases were divided into rtPA group (31 cases) and urokinase (UK) group (35 cases),which were treated with low dose rtPA and UK,respectively.Results:The clinical reperfusion rates of infarctrelated arteries in rtPA and UK groups were 80 6% and 48 6%,respectively ( P <0 05).The total 4week mortality in rtPA and UK groups were 0 and 8 6% ( P <0 05),respectively,but bleeding rate in 2 groups was not markedly different.Conclusions:The results suggest that low dose rtPA appears to be an effective,reliable and safe thrombolytic agent for AMI.